期刊文献+

舒尔痛分散片单次给药剂量人体耐受性试验

A phase I tolerance and safety study of Shuertong dispersible tablet
原文传递
导出
摘要 目的:观察健康受试者对舒尔痛分散片单次给药剂量的耐受性和安全性,为多次给药及Ⅱ期临床试验推荐安全剂量。方法:单次给药试验中30例受试者随机分为6个剂量组,分别给予舒尔痛分散片0.44,0.88,1.32,2.2,3.08和3.52g。观察受试者的临床症状、生命体征、实验室检查、心电图检查及不良事件等。结果:30例受试者全部完成耐受性试验,单次给药剂量下所有受试者未见重要生命体征有明显改变,无不良事件发生。结论:舒尔痛分散片在0.44~3.52g剂量范围内单次给药安全性和耐受性良好,最大耐受剂量为3.52g,推荐多次给药剂量为2.2g·d^-1。 Objective: To observe the tolerance and safety of healthy subjects to Shuertong dispersible tab- let, and to recommend the safe dosage for continuous medication trial and phase Ⅱ clinical trial. Methods: Thirty healthy volunteers attended the single dose trial. They received 6 doses (0.44, 0.88, 1.32, 2.2, 3.08 and 3.52 g) randomly. The safety was evaluated based on clinical symptoms, vital signs, laboratory tests, ECG and adverse e- vents. Results: All the 30 healthy volunteers completed the tolerance test. Significant changes in vital signs, AE and SAE were not observed in all subjects in single dose trials. Conclusion: Shuertong dispersible tablet is well tolerated and safe in healthy volunteers. The maximal tolerance dosage is 3.52 g daily. The dose regimen of 2.2 g. d^-1 is recommended for continuous medication trials.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第9期1063-1065,共3页 Chinese Journal of New Drugs
关键词 舒尔痛分散片 I期临床试验 安全性 耐受性 Shuertong dispersible tablet phase Ⅰ clinical trial safety tolerance
  • 相关文献

参考文献10

二级参考文献94

共引文献154

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部